Best targeted sarcoma treatment: advances from the Musculoskeletal Tumor Society annual meeting.

摘要

Targeted, personalized therapy is the mantra in contemporary oncology. In the rapidly changing political, legal, and medical landscape, there are challenges and successes for musculoskeletal cancer patients, practitioners, and researchers as we try to implement individualized therapies. The Musculoskeletal Tumor Society (MSTS) leads, captures, and reflects the societal dynamism that will determine how personalized medicine applies to bone and soft tissue tumors through the activities of the MSTS members (Fig. 1), their annual meeting, and the selected papers published in this Clinical Orthopaedics and Related Research? symposium. During this past year, three major regulatory and legal changes have occurred: (1) the U.S. Supreme Court ruled [1] that genes cannot be patented, (2) the FDA approved [6] genome-wide genetic testing, and (3) the FDA restricted [7] the company 23andMe Inc.